Biotech Values

[jbog]

Clinical trials where the efficacy endpoint is subjective (i.e. how the patient feels rather than an empirical measurement) tend to have high failure rates even if the drug being tested has bona fide activity.

Revance is in the single digits because of the exact points you make. All the skin care trials are subjective and sadly the customer is the judge and jury.